Journal
PHARMACOTHERAPY
Volume 22, Issue 6, Pages 771-774Publisher
PHARMACOTHERAPY PUBLICATIONS INC
DOI: 10.1592/phco.22.9.771.34071
Keywords
-
Categories
Ask authors/readers for more resources
Rhabdomyolysis is an uncommon complication associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. We observed six cases of cerivastatin-associated rhabdomyolysis: two patients developed acute renal failure requiring hemodialysis, and one patient died. Four of the patients had impaired renal function, and five were prescribed drugs with the potential to interact with cerivastatin. Also, five of the six patients presented with symptoms of rhabdomyolysis 3-4 weeks after starting cerivastatin therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available